Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2025-07-31 Director's Dealing
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by Seo Jung-jin, an executive of Celltrion. This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading activities, specifically the purchase of company shares by a director. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2025-07-31 Korean
투자판단관련주요경영사항 (미국 원료의약품 시설 보유한 기업 인수에 대한 독점 교섭 확약 체결 (우선협상대상자 선정))
M&A Activity Classification · 100% confidence The document is a regulatory filing from Celltrion regarding a 'major management matter' (투자판단 관련 주요경영사항). It specifically announces that the company has been selected as the preferred bidder for the acquisition of a US-based active pharmaceutical ingredient (API) manufacturing facility. This falls under M&A activity (merger/acquisition/takeover bids).
2025-07-29 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). Specifically, it details the disposal of treasury shares due to the exercise of stock options by employees. According to the filing definitions, the category 'Transaction in Own Shares' (POS) is the correct classification for reports concerning a company buying back or selling/disposing of its own shares.
2025-07-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by Seo Jung-jin, the Chairman of Celltrion. This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading activities (purchases of shares by a director). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2025-07-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. It details the shareholding status of the major shareholder (Celltrion Holdings) and its special related parties in the issuer (Celltrion). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-07-23 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (잠정실적) for Celltrion for the second quarter of 2025. It provides key financial highlights such as revenue and operating profit, explicitly stating these are preliminary figures provided for investor convenience before the final audit. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results. Q2 2025
2025-07-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.